Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Another milestone in the evolution of GLP-1-based diabetes therapies

The first clinical study of an oral small-molecule GLP-1 receptor agonist suggests effective glycemic control and weight loss in patients with type 2 diabetes.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Milestones in the clinical development of GLP-1-based glucose-lowering therapies.


  1. 1.

    Parker, J. C. et al. J. Pept. Res. 52, 398–409 (1998).

    CAS  Article  Google Scholar 

  2. 2.

    Saxena, A. R. et al. Nat. Med. (2021).

    Article  Google Scholar 

  3. 3.

    Sloop, K. W. et al. Diabetes 59, 3099–3107 (2010).

    CAS  Article  Google Scholar 

  4. 4.

    Holst, J. J., Ørskov, C., Vagn-Nielsen, O. & Schwartz, T. W. FEBS Lett. 211, 169–174 (1987).

    CAS  Article  Google Scholar 

  5. 5.

    Nauck, M. A. Metabolism 103, 154031 (2020).

    CAS  Article  Google Scholar 

  6. 6.

    Nauck, M. A. & Meier, J. J. Eur. J. Endocrinol. 181, R211–R234 (2019).

    CAS  Article  Google Scholar 

  7. 7.

    Nauck, M. A., Quast, D. R., Wefers, J. & Meier, J. J. Mol. Metab. 46, 101102 (2020).

    Article  Google Scholar 

  8. 8.

    Davies, M. et al. J. Am. Med. Assoc. 318, 1460–1470 (2017).

    CAS  Article  Google Scholar 

  9. 9.

    Gabery, S. et al. JCI Insight 5, e133429 (2020).

    Article  Google Scholar 

  10. 10.

    Nauck, M. A., Kemmeries, G., Holst, J. J. & Meier, J. J. Diabetes 60, 1561–1565 (2011).

    CAS  Article  Google Scholar 

  11. 11.

    Meier, J. J. et al. Diabetes Care 38, 1263–1273 (2015).

    CAS  Article  Google Scholar 

  12. 12.

    Kawai, T. et al. Proc. Natl Acad. Sci. USA 117, 29959–29967 (2020).

    CAS  Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Michael A. Nauck.

Ethics declarations

Competing interests

M.A.N. has been member on advisory boards or has consulted with AstraZeneca, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Menarini/Berlin Chemie, Merck, Sharp & Dohme, and NovoNordisk; has received grant support from AstraZeneca, Eli Lilly, Menarini/Berlin-Chemie, Merck, Sharp & Dohme, and NovoNordisk; and has served on the speakers’ bureau of AstraZeneca, Boehringer Ingelheim, Eli Lilly, Menarini/Berlin Chemie, Merck, Sharp & Dohme, and NovoNordisk. J.J.M. has received consulting and speaker honoraria from AstraZeneca, Eli Lilly, Merck, Sharp & Dohme, Novo Nordisk, Sanofi and Servier; and has received research support from Boehringer-Ingelheim, Eli Lilly &, Merck, Sharp & Dohme, Novo Nordisk, and Sanofi.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Nauck, M.A., Quast, D.R. & Meier, J.J. Another milestone in the evolution of GLP-1-based diabetes therapies. Nat Med 27, 952–953 (2021).

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing